Eastenova key facts
as of Oct 2026- Developer of regenerative medical devices and foods to be used in various regenerative medical treatments.
- Eastenova is valued at approximately $206.8M as of Oct 2026 (last reported valuation).
- It has raised $28.0M; the latest was IPO in May 2025.
- Notable investors include Shenzhen Capital Group, Chengdu Jiaozi Financial Holding Group, China Medical System, SUNNOVO, Shenzhen HTI Group.
- Status: In IPO Registration.
Eastenova's last reported valuation, Mar 2025. Nothing priced has surfaced since.
- ·Watch Eastenova: the Monday email on marks, rounds and moves
Eastenova funding rounds
No funding rounds for Eastenova are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Eastenova valuation
Eastenova's last reported valuation was $207 million in Mar 2025. No priced round, secondary trade or fund mark has surfaced since.
Eastenova investors
5 investors are on record for Eastenova, including Shenzhen Capital Group, Chengdu Jiaozi Financial Holding Group, China Medical System and SUNNOVO.
About Eastenova
Developer of regenerative medical devices and foods to be used in various regenerative medical treatments. The company's therapeutics provide regenerative support in repairing lost cells and tissue, enabling physicians to prescribe effective healing treatments.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2016
- Employees
- 185
- Website
- dfyanmei.com/
- Ownership
- In IPO Registration
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.